908 Devices Inc.
Analysis at the Speed of Life We are making chemical analysis simple, smart and speedy with our purpose-built handheld devices that empower people to take swift action in life-altering applications. Company Overview We have developed an innovative suite of purpose-built handheld devices for point-of-need chemical analysis.
$11.54
-$0.27 (-2.25%)
Live
The business is unprofitable at the operating level (-70.15% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 17.7% YoY with margins expanding 50.1pp.
Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$61M
▲ +17.7% YoY
Net Income (TTM)
-$35M
▲ +127.0% YoY
Op. Margin
-63.98%
▲ +50.1pp YoY
ROIC
-22.02%
▲ +7.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$615K
▲ +20.1% YoY
Op. Cash Flow (TTM)
$1M
▲ +21.7% YoY
Net Debt
-$97M
Net Cash Position
Cash & Equiv.
$102M
5Y CAGR: +15.9%
Continue Research
SourceComputed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Price from market data, live as of 22 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is 908 Devices (MASS) overvalued?
908 Devices (MASS) trades above a two-stage DCF intrinsic value of about $2.98 per share, so at $11.54 the stock looks overvalued (74.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, 908 Devices scores 51/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is 908 Devices's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $2.98 per share for MASS, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $2.24. At today's $11.54, that puts the stock about 74.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is 908 Devices a high-quality business?+
908 Devices scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -64.0% operating margin and a -22.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is 908 Devices a good stock to buy right now?+
That depends on valuation and quality together, not either alone. MASS currently trades above its estimated intrinsic value and scores 51/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Laboratory Analytical Instruments
Spot a number that looks wrong? Check it in MASS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MASS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.